NCT05273814

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Phase I Clinical Study of Tislelizumab in Combination With Bevacizumab and Pemetrexed for the First-line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients

• Status: Unknown
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Tianjin Medical University Cancer Institute and Hospital · Academic / Other
• Sex: All
• Age: 65 Years
• Healthy volunteers: Not accepted

Summary

This single-center, open-label, phaseⅠstudy is to evaluate the efficacy of Tislelizumab in combination with Bevacizumab and Pemetrexed for the first-line treatment of advanced Non-squamous Non-small Cell lung cancer in Elderly Patients

Detailed description

Patients received Bevacizumab, 7.5mg/kg d1, Pemetrexed, 500mg/m2, d1 and Tislelizumab 200mg, d4, Q3W, for 4 cycles; then Tislelizumab 200mg, d1 Q3w and Bevacizumab 7.5mg/kg d1 Q3W, maintenance treatment for 2 years.

Conditions

• Non-Small Cell Lung Cancer

Interventions

Type	Name	Description
DRUG	Tislelizumab	Tislelizumab intravenous infusion 200mg d4
DRUG	Pemetrexed	Pemetrexed intravenous infusion 500mg/m2 d1
DRUG	Bevacizumab	Pemetrexed intravenous infusion 7.5mg/kg，d1

Timeline

• Start date: 2022-08-01
• Primary completion: 2023-08-01
• Completion: 2024-02-01
• First posted: 2022-03-10
• Last updated: 2022-07-13

Locations

1 site across 1 country: China